[
    "metabolism.</p>The term \u201ccompounds of the disclosure\u201d refers to any of the compounds described herein based on any combination of structural and/or functional features, including compounds of formula (I) (including compounds of formulae (Ia) and formula (Ib)), formulae (II) (including compounds of formulae (IIa) and (IIb)), formulae (III) (including compounds of formulae (IIIa) and (IIIb)), formula IV (including compounds of formulae (Iva) and (IVb)), formula (V) (including compounds of formulae (Va) and (Vb)), or formula (VI) (including compounds of formulae (VIa) and (VIb)), wherein the variables are defined as provided herein, as well as to any of the specific compounds described herein. The term \u201ccompounds of the disclosure\u201d refers, unless context indicates otherwise, to salts of such compounds, such as pharmaceutically acceptable salts. In certain embodiments, compounds of the disclosure are capable of inhibiting SHMT activity, such as enzyme activity. In certain embodiments, compounds of the disclosure are inhibitors of SHMT2 and, optionally, SHMT1. In certain embodiments, compounds of the disclosure are selective inhibitors of SHMT (e.g., SHMT1 and/or 2). In certain embodiments, compounds of the disclosure are selective for SHMT over MTHFD2 and/or DHFR and/or TS. For example, in certain embodiments, compounds of the disclosure either do not inhibit or inhibit one or more of MTHFD2, DHFR, FH, TS and/or another protein involved in mitochondrial folate metabolism with an IC50 at least 25 fold, at least 50 fold, at least 75 fold, at least 100 fold, at least 200 fold, at least 500 fold, at least 1000 fold, or greater than 1000 fold less than that for SHMT2 and/or SHMT1.</p>In certain embodiments, compounds of the disclosure include compounds provided as a pharmaceutical composition.</p>Compounds of the disclosure also include tautomeric forms, such as keto-enol tautomers, prototropic tautomers, and the like, for example annular tautomers wherein a proton can occupy two or more positions on a heteroaryl system. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present disclosure.</p>Compounds of the disclosure also include all isotopes of atoms occurring in the intermediates and/or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include deuterium and tritium.</p>Compounds of formula I (including compounds of formula Ia and formula Ib) and II, III, IV, V, or VI (and the other compounds of the disclosure) have one or more chiral centers and therefore can exist as enantiomers and/or diastereomers. Compounds of formula (I) (including compounds of formula (Ia) and formula (Ib)) and (II), (III), (IV), (V), or (VI) (and the other compounds of the disclosure) may also exist as stereoisomers, for example atropisomers, r",
    " unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a pharmaceutically acceptable salt thereof.\n</p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (Ia) (wherein the R groups are as described above for Formula (I):</p><img id=\"EMI-C00003\" path=\"US20200237725A1-20200730-C00003.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293889/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00003.TIF\"/></p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (Ib) (wherein the R groups are as described above for Formula (I)):</p><img id=\"EMI-C00004\" path=\"US20200237725A1-20200730-C00004.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293938/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00004.TIF\"/></p>In certain embodiments, any of the compounds of Formula (I) (including of Formula Ia or Ib) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.)</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein.</p>In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In certain embodiments of any of the foregoing or following, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, or \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, subst",
    "eof.</p>In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula I are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula I are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula I are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula I inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula I inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM.</p>In certain embodiments, compounds of Formula I described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SHMT activity in vitro or in vivo, or to treat cancer.</p>In one aspect, the disclosure provides compounds represented by general Formula (II):</p><img id=\"EMI-C00008\" path=\"US20200237725A1-20200730-C00008.TIF\" file=\"https://surechembl.org/api/assets/attachment/761294033/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00008.TIF\"/></p>wherein:</p>Z is N or CR<sup>4</sup>;X is O, S, CH<sub>2</sub>, or NR<sup>6</sup>;\nR<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>,\n\n\u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014OC(O)R<sup>12</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substi",
    " unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a pharmaceutically acceptable salt thereof.\n\n</p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (IIa) (wherein the R groups are as described above for Formula (II)):</p><img id=\"EMI-C00009\" path=\"US20200237725A1-20200730-C00009.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293913/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00009.TIF\"/></p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented Formula (IIb) (wherein the R groups are as described above for Formula (II)):</p><img id=\"EMI-C00010\" path=\"US20200237725A1-20200730-C00010.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293917/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00010.TIF\"/></p>In certain embodiments of any of the foregoing or following, any of the compounds of Formula II (including of Formula IIa or IIb) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.)</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein.</p>In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In certain embodiments of any of the foregoing or following, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted haloalkyl, or substituted or unsubstituted C<sub>1",
    "</p>In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula II are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula II are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula II are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula II inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula II inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM.</p>In certain embodiments, compounds of Formula II described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SHMT activity in vitro or in vivo, or to treat cancer.</p>In certain embodiments, when Z is N, and R<sup>8 </sup>is \u2014H, R<sup>7 </sup>cannot be substituted or unsubstituted aryl.</p>In certain embodiments, the compound of formula II, IIa, or IIb is not</p><img id=\"EMI-C00011\" path=\"US20200237725A1-20200730-C00011.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293914/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00011.TIF\"/></p>In certain embodiments, when R<sup>4 </sup>and R<sup>5 </sup>taken together with the respective carbon atoms to which they are attached for a substituted aryl ring, R<sup>8 </sup>is not \u2014H, \u2014OH, or \u2014CN.</p>In certain embodiments, the compound of formula (II), (IIa), or (IIb) is:</p><img id=\"EMI-C00012\" path=\"US20200237725A1-20200730-C00012.TIF\" file=\"https://surechembl.org/api/assets/attachment/761294058/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00012.TIF\"/></p>or a phar",
    "oalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a pharmaceutically acceptable salt thereof.\n</p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (IIIa) (wherein the R groups are as described above for Formula (III)):</p><img id=\"EMI-C00014\" path=\"US20200237725A1-20200730-C00014.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293998/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00014.TIF\"/></p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (IIIb) (wherein the R groups are as described above for Formula (III)):</p><img id=\"EMI-C00015\" path=\"US20200237725A1-20200730-C00015.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293935/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00015.TIF\"/></p>In certain embodiments, any of the compounds of Formula (III) (including of Formula (IIIa) or (IIIb)) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.).</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein. In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In certain embodiments of any of the foregoing or following, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>11</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, or \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>haloalkyl, or substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>haloalkoxy.</p>In certain embodiments of any of the foregoing or following, R<sup>0 </sup>is selected from hydroxyl, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</",
    "In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula III are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula III are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula III are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula III inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula III inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM. In certain embodiments, compounds of Formula III described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SI-MT activity in vitro or in vivo, or to treat cancer.</p>In certain embodiments, when R<sup>8 </sup>is \u2014H, R<sup>2 </sup>is not a substituted or unsubstituted aryl.</p>In one aspect, the disclosure provides compounds represented by general Formula (IV):</p><img id=\"EMI-C00017\" path=\"US20200237725A1-20200730-C00017.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293942/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00017.TIF\"/></p>wherein:\n\nR<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>,\n\n\u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014OC(O)R<sup>12</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<s",
    "nsubstituted aryl, or substituted or unsubstituted heteroaryl, or a pharmaceutically acceptable salt thereof.\n</p>In certain embodiments of any of the foregoing or following, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (IVa) (wherein the R groups are as described above for Formula (IV)):</p><img id=\"EMI-C00018\" path=\"US20200237725A1-20200730-C00018.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293949/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00018.TIF\"/></p>In certain embodiments of any of the foregoing or following, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (IVb) (wherein the R groups are as described above for Formula (IV)):</p><img id=\"EMI-C00019\" path=\"US20200237725A1-20200730-C00019.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293961/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00019.TIF\"/></p>In certain embodiments, any of the compounds of Formula (IV) (including of Formula (Iva) or (IVb)) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.)</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein.</p>In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In certain embodiments of any of the foregoing or following, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014OC(O)R<sup>12</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or uns",
    "</p>In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula IV are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula IV are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula IV are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula IV inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula IV inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM.</p>In certain embodiments, compounds of Formula IV described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SHMT activity in vitro or in vivo, or to treat cancer.</p>In certain embodiments, the compound of Formula (IV), (Iva), or (IVb) is not</p><img id=\"EMI-C00022\" path=\"US20200237725A1-20200730-C00022.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293927/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00022.TIF\"/></p>In one aspect, the disclosure provides compounds represented by general Formula (V):</p><img id=\"EMI-C00023\" path=\"US20200237725A1-20200730-C00023.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293979/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00023.TIF\"/></p>wherein:\n\nA, D, G and K are each independently N or CR<sup>15</sup>, provided that no more than two of A, D, G, and K are N simultaneously;\n\nR<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</su",
    "yl, or substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>haloalkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>haloalkoxy, or a pharmaceutically acceptable salt thereof.\n</p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (Va) (wherein the R groups are as described above for Formula (V)):</p><img id=\"EMI-C00024\" path=\"US20200237725A1-20200730-C00024.TIF\" file=\"https://surechembl.org/api/assets/attachment/761294027/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00024.TIF\"/></p>In certain embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, are represented by Formula (Vb) (wherein the R groups are as described above for Formula (V)):</p><img id=\"EMI-C00025\" path=\"US20200237725A1-20200730-C00025.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293936/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00025.TIF\"/></p>In certain embodiments, any of the compounds of Formula (V) (including of Formula (Va) or (Vb)) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.)</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein.</p>In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In certain embodiments of any of the foregoing or following, R<sup>0</sup>, R<sup>1</sup>, and R<sup>2</sup>, are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>11</sup>, \u2014NS(O)<sub>2</sub>R<sup>12</sup>, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted C<sub>1</",
    ".</p>In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula V are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula (V) are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula V are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula V inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula (V) inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM.</p>In certain embodiments, compounds of Formula (V) described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SHMT activity in vitro or in vivo, or to treat cancer.</p>In certain embodiments of any of the foregoing or following, the disclosure provides a pharmaceutical composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients and/or solvents.</p>In another aspect of any of the foregoing or following, the disclosure provides a method of inhibiting the activity of a mammalian serine hydroxymethyl transferase (SHMT) enzyme, comprising contacting the enzyme or a cell expressing the enzyme with a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein.</p>In certain embodiments of any of the foregoing or following, the mammalian SHMT enzyme is a human SHMT enzyme.</p>In certain embodiments of any of the foregoing or following, the SHMT enzyme is SHMT2.</p>In certain embodiments of any of the f",
    "d\n\neach occurrence of R<sup>10 </sup>and R<sup>12 </sup>is each independently selected from \u2014H, substituted or unsubstituted C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.\n</p>In some embodiments, the compound is represented by Formula (VIa) (wherein the R groups are as described above for Formula (VI)):</p><img id=\"EMI-C00028\" path=\"US20200237725A1-20200730-C00028.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293860/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00028.TIF\"/></p>In certain embodiments, the compound is represented by Formula (VIb) (wherein the R groups are as described above for Formula (VI)):</p><img id=\"EMI-C00029\" path=\"US20200237725A1-20200730-C00029.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293980/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00029.TIF\"/></p>In certain embodiments, any of the compounds of Formula (VI) (including of Formula (VIa) or (VIb)) described herein, or a pharmaceutically acceptable salt thereof, are capable of inhibiting activity of an SHMT enzyme (e.g., are SHMT inhibitors, such as an SHMT2 inhibitor). Any such compounds described based on any of the structural features described herein may, in certain embodiments, also be described based on any of the functional features described herein (e.g., binding affinity for SHMT1 and/or 2, IC50, selectivity, inhibitory effect on serine flux or mitochondrial serine flux, etc.)</p>In certain embodiments of any of the foregoing or following, a compound of the disclosure is provided in isolated or substantially purified form, such as a substantially purified stereoisomer of a compound of the disclosure. Without being bound by theory, compounds of the disclosure have a stereocenter. Thus, in certain embodiments, substantially purified stereoisomers are provided and are suitable in any of the methods described herein.</p>In certain embodiments, the disclosure provides a pharmaceutically acceptable salt of any of the compounds of the disclosure.</p>In another aspect, the disclosure provides a method for treating a disorder associated with activity of a serine hydroxymethyl transferase (SHMT) enzyme and/or associated with alterations in mitochondrial metabolism, such as mitochondrial folate metabolism, comprising administering to a subject in need thereof an effective amount of a compound of Formula (VI) or a pharmaceutically acceptable salt thereof:</p><img id=\"EMI-C00030\" path=\"US20200237725A1-20200730-C00030.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293984/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00030.TIF\"/></p>wherein:\n\nR<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12",
    "</p>In certain embodiments of any of the foregoing or following, the R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not all simultaneously \u2014H. In other embodiments, R<sup>0 </sup>is \u2014H and the ring to which it is attached, is substituted with a single substituent (other than \u2014H) at one of R<sup>1 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>0 </sup>is \u2014H, and R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>1 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than \u2014H) at one of R<sup>0 </sup>or R<sup>2</sup>. In certain embodiments, R<sup>1 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>2 </sup>are not \u2014H. In other embodiments, R<sup>2 </sup>is \u2014H and the ring to which it is attached is substituted with a single substituent (other than H) at one of R<sup>0 </sup>or R<sup>1</sup>. In certain embodiments, R<sup>2 </sup>is \u2014H, and R<sup>0 </sup>and R<sup>1 </sup>are not \u2014H. In other embodiments, R<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are not \u2014H.</p>In certain embodiments of any of the foregoing or following, compounds of Formula VI are inhibitors of SHMT, such as are capable of inhibiting an activity of an SHMT enzyme. In certain embodiments, compounds of Formula VI are SHMT2 inhibitors and, optionally, are also inhibitors of SHMT1. In certain embodiments, compounds of Formula VI are SHMT2 inhibitors, but do not inhibit SHMT1. In certain embodiments, compounds of Formula VI inhibit SHMT2 with an IC50 of less than 5000 nM and, optionally, inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, compound of Formula VI inhibit SHMT2 with an IC50 of less than 2000 nM, less than 1500 nM, less than 800 nM, less than 500 nM, less than 250 nM, less than 150 nM, or less than 50 nM. In certain embodiments, such compounds also inhibit SHMT1 with an IC50 of less than 5000 nM. In certain embodiments, such compounds inhibit SHMT1 with an IC50 of less than 1000 nM, less than 750 nM, less than 500 nM, less than 250 nM, less than 100 nM, or less than 50 nM. In certain embodiments, the IC50 is measured in an in vitro assay, as described herein. In certain embodiments, compounds are selective inhibitors, as described herein.</p>In certain embodiments, compounds of Formula (VI) described using any combination of structural and/or functional activity, including any combination of one or more features described above or herein, are provided (and may be provided as an isolated or purified form or as a pharmaceutical composition). In certain embodiments, any such compounds of the disclosure may be used in any of the methods described herein, such as to inhibit SHMT activity in vitro or in vivo, or to treat cancer.</p>In another aspect, the disclosure provides a pharmaceutical composition for inhibiting the activity of a mammalian serine hydroxymethyl transferase (SHMT) enzyme, comprising a compound of Formula (VI) or a pharmaceutically acceptable salt thereof:</p><img id=\"EMI-C00039\" path=\"US20200237725A1-20200730-C00039.TIF\" file=\"https://surechembl.org/api/assets/attachment/761293905/US/20200730/A1/020200/23/77/25/US20200237725A1-20200730-C00039.TIF\"/></p>wherein:\n\nR<sup>0</sup>, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from \u2014H, halogen, hydroxyl, nitro, nitrile, \u2014SOR<sup>11</sup>, \u2014S(O)<sub>2</sub>R<sup>11</sup>, \u2014S(O)<sub>2</sub>NR<sup>10</sup>R<sup>12</sup>, \u2014OR<sup>11</sup>, \u2014OC(O)R<sup>12</sup>, \u2014C(O)OR<sup>12</sup>, \u2014C(O)R<sup>11</sup>, \u2014C(O)NR<sup>10</sup>R<sup>12</sup>, \u2014NR<sup>10</sup>R<sup>12</sup>, \u2014N(R<sup>12</sup>)C(O)R<sup>1"
]